Ryvu Therapeutics SA
- Country
- 🇵🇱Poland
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 276
- Market Cap
- -
- Website
- http://ryvu.com
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 178
- Registration Number
- NCT06534437
- Locations
- 🇫🇷
Centre Hospitalier Le Mans, Le Mans, France
🇫🇷CHU de Limoges - CHU Dupuytren, Limoges CEDEX 1, France
🇫🇷Hospices Civils De Lyon - Hôpital Lyon Sud, Lyon, France
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 230
- Registration Number
- NCT06397313
- Locations
- 🇮🇹
Policlinico Sant'Orsola-Malpighi, Bologna, Italy
🇮🇹Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
🇮🇹Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco", Catania, Italy
Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML
- Conditions
- High-risk Myelodysplastic SyndromeAcute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 94
- Registration Number
- NCT06268574
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Spain
🇪🇸Virgen del RocÃo University Hospital, Sevilla, Spain
🇮🇹Ospedale Vito Fazzi Lecce, Lecce, Italy
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 98
- Registration Number
- NCT06191263
- Locations
- 🇮🇹
AUSL Romagna - Ospedale S.M. Delle Croci, Ravenna, Italy
🇮🇹Istituto Clinico Humanitas, Rozzano, Italy
🇵🇱PRATIA Onkologia Katowice, Katowice, Poland
RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 120
- Registration Number
- NCT05052255
- Locations
- 🇵🇱
Beskidzkie Centrum Onkologii, Szpital Miejski im., Bielsko-Biała, Poland
🇵🇱Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz, Gdańsk, Poland
🇵🇱UCK im. prof. K. Gibińskiego, Katowice, Poland
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid LeukemiaHigh-risk Myelodysplastic Syndrome
- Interventions
- Drug: RVU120(SEL120)
- First Posted Date
- 2019-07-16
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Ryvu Therapeutics SA
- Target Recruit Count
- 112
- Registration Number
- NCT04021368
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami, Florida, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States